It appears you don't have support to open PDFs in this web browser. To view this file, Open with your PDF reader
Abstract
Maintenance of genome integrity requires tight control of DNA damage response (DDR) signalling and repair, with phosphorylation and ubiquitination representing key elements. How these events are coordinated to achieve productive DNA repair remains elusive. Here we identify the ubiquitin-conjugating enzyme UBE2D3 as a regulator of ATM kinase-induced DDR that promotes non-homologous end-joining (NHEJ) at telomeres. UBE2D3 contributes to DDR-induced chromatin ubiquitination and recruitment of the NHEJ-promoting factor 53BP1, both mediated by RNF168 upon ATM activation. Additionally, UBE2D3 promotes NHEJ by limiting RNF168 accumulation and facilitating ATM-mediated phosphorylation of KAP1-S824. Mechanistically, defective KAP1-S824 phosphorylation and telomeric NHEJ upon UBE2D3-deficiency are linked to RNF168 hyperaccumulation and aberrant PP2A phosphatase activity. Together, our results identify UBE2D3 as a multi-level regulator of NHEJ that orchestrates ATM and RNF168 activities. Moreover, they reveal a negative regulatory circuit in the DDR that is constrained by UBE2D3 and consists of RNF168- and phosphatase-mediated restriction of KAP1 phosphorylation.
Ubiquitin system factors are critical regulators of DNA repair pathways. Through a functional genetic screen, the authors identify a novel role of ubiquitin-conjugating enzyme UBE2D3 in promoting DNA repair at deprotected telomeres by limiting the accumulation of RNF168 and promoting ample ATM-dependent phosphorylation of KAP1.
You have requested "on-the-fly" machine translation of selected content from our databases. This functionality is provided solely for your convenience and is in no way intended to replace human translation. Show full disclaimer
Neither ProQuest nor its licensors make any representations or warranties with respect to the translations. The translations are automatically generated "AS IS" and "AS AVAILABLE" and are not retained in our systems. PROQUEST AND ITS LICENSORS SPECIFICALLY DISCLAIM ANY AND ALL EXPRESS OR IMPLIED WARRANTIES, INCLUDING WITHOUT LIMITATION, ANY WARRANTIES FOR AVAILABILITY, ACCURACY, TIMELINESS, COMPLETENESS, NON-INFRINGMENT, MERCHANTABILITY OR FITNESS FOR A PARTICULAR PURPOSE. Your use of the translations is subject to all use restrictions contained in your Electronic Products License Agreement and by using the translation functionality you agree to forgo any and all claims against ProQuest or its licensors for your use of the translation functionality and any output derived there from. Hide full disclaimer
Details









1 The Netherlands Cancer Institute, Division of Oncogenomics, Amsterdam, the Netherlands (GRID:grid.430814.a) (ISNI:0000 0001 0674 1393)
2 Leiden University Medical Center, Department of Cell and Chemical Biology, Leiden, the Netherlands (GRID:grid.10419.3d) (ISNI:0000 0000 8945 2978)
3 The Netherlands Cancer Institute, Proteomics Facility, Amsterdam, the Netherlands (GRID:grid.430814.a) (ISNI:0000 0001 0674 1393)
4 Leiden University Medical Center, Department of Cell and Chemical Biology, Leiden, the Netherlands (GRID:grid.10419.3d) (ISNI:0000 0000 8945 2978); Universidad de Sevilla-CSIC-Universidad-Pablo de Olavide, Andalusian Center for Molecular Biology and regenerative Medicine (CABIMER), Sevilla, Spain (GRID:grid.427489.4) (ISNI:0000 0004 0631 1969); Universidad de Sevilla, Departamento de Biología Celular, Facultad de Biología, Sevilla, Spain (GRID:grid.9224.d) (ISNI:0000 0001 2168 1229)